Abstract
Transmissible spongiform encephalopathy (TSE) is an inclusive term for a group of slowly progressing, neurodegenerative diseases with long incubation periods. Design and validation of manufacturing processes that eliminate TSE agents is difficult because of TSE resistance to standard chemical and physical measures and the lack of quick, reliable diagnostic assays. Thus, preventive measures have been put into place by regulatory authorities. Bovine spongiform encephalopathy (BSE), the cause of “mad cow disease,” is of particular concern since it is believed to cause CreutTfeld-Jakob disease in humans. Many medicinal products contain or come in contact with substances of bovine origin during manufacture. As a consequence, regulations and guidances have been established in the United States and Europe for bovine-derived materials used in manufacturing medicinal products. Manufacturers must assess active substances, excipients, raw materi¬als, production reagents, and materials coming into direct contact with manufacturing equipment or product containers. United States and European regulatory authorities have used different approaches toward documentation required for bovine materials used in the production of medicinal products. The relevant documentation must be included in the investigational or marketing application.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bovine Spongiform Encephalopathy. Fact sheet. Washington, DC: US Department of Agriculture, Veterinary Services, Animal and Plant Health Inspection Service (APHIS); September 1999.
Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Medicinal Products. Reference, No. CPMP/BWP/1230/98. London, England: European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products, Human Medicines Evaluation Unit; April 1999. Available at http://www.eudra.org.
“Workshop on Standards for Inactivation and Clearance of Infectious Agents in the Manufacture of Plasma Derivatives from Non-human Source Materials for Human Injectable Use,” sponsored by Center for Biologies Evaluation and Research, FDA. Bethesda, MD, October 25, 1999.
The BSE Inquiry: The Report. British Government Report. London, England: The House of Commons, The Stationary Store, UK Government; October 2000. http://www.bseinquiry.gov.uk.
Bovine Spongiform Encephalopathy and Creutz-feldt-Jakob Disease. Fact Sheet. Rockville, MD, US Food and Drug Administration, Center for Veterinary Medicine; January 2, 1997. http://www.fda.gov/cvm.
Bruce, ME, Will, RG, Ironside, JW, et al. Transmissions to mice indicate that ‘new variant’ CJD is caused by the BSE agent. Nature. 1997;389(6650): 498–501.
Hill, AF, Desbruslais, M, Joiner, S, et al. The same prion strain causes vCJD and BSE. Nature. 1997; 389(6650):448–450.
Collinge, J, Sidle, KC, Meads, J, Ironside, J, Hill, AF. Molecular analysis of prion strain variation and the aetiology of ‘new variant’ CJD. Nature. 1996; 383(6602):685–690.
Final Opinion of the Scientific Steering Committee on the Geographical Risk of Bovine Spongiform Encephalopathy (GBR). Brussels, Belgium: European Union, European Commission, Scientific Steering Committee, Food Safety; adopted on July 6, 2000. http://europa.eu.int/comm/food/fs/sc/ssc/outU3_en.pdf.
“International Workshop on Diagnostics for Transmissible Spongiform Encephalopathies (TSEs),” sponsored by US Food and Drug Administration and US National Institutes of Health National Institute of Neurological Disorders and Stroke. Bethesda, MD, September 20–22, 2000.
9 CFR 94.18. Restrictions on importation of meat and edible products from ruminants due to bovine spongiform encephalopathy. January 1,2000 edition.
9 CFR 94.19. Gelatin derived from horses or swine, or from ruminants that have not been in any region where bovine spongiform encephalopathy exists. January 1, 2000 edition.
Guidance for Industry: The Sourcing and Processing of Gelatin to Reduce the Potential Risk Posed by Bovine Spongiform Encephalopathy (BSE) in FDA-Regulated Products for Human Use. Rockville, MD: US Food and Drug Administration; September 1997. http://www.fda.gov/opacom/morechoices/industry/guidance/gelguide.htm.
Guidance for Industry 67: Small Entities Compliance Guide for Renderers. Rockville, MD: US Food and Drug Administration; February 1998. http://www.fda.gov/cvm.
Guidance for Industry 68: Small Entities Compliance Guide for Protein Blenders, Feed Manufacturers, and Distributors. Rockville, MD: US Food and Drug Administration; February 1998. http://www.fda.gov/cvm.
Guidance for Industry 69: Small Entities Compliance Guide for Feeders of Ruminant Animals with On-farm Feed Mixing Operations. Rockville, MD: US Food and Drug Administration; February 1998. http://www.fda.gov/cvm.
Guidance for Industry 70: Small Entities Compliance Guide for Feeders of Ruminant Animals Without On-farm Feed Mixing Operations. Rockville, MD: US Food and Drug Administration; February 1998. http://www.fda.gov/cvm.
Guidance for Industry 76: Questions and Answers on BSE Feed Regulation. Rockville, MD: US Food and Drug Administration; July 1998. http://www.fda.gov/cvm.
Letter to Manufacturers of FDA-Regulated Products. Rockville, MD: US Food and Drug Administration; December 17, 1993. Printed in Federal Register, August 29, 1994 (59 FR 44592).
Letter to Manufacturers of Biological Products. Center for Biologies Evaluation and Research. Rockville, MD: US Food and Drug Administration; April 19, 2000.
USDA to Destroy Three Vermont Sheep Flocks Quarantined for TSE. News Release, No. 0235.00. Washington, DC: US Department of Agriculture; July 14, 2000.
Transmissible Spongiform Encephalopathies (TSE). Backgrounder. Washington, DC: US Department of Agriculture, Veterinary Services, Animal and Plant Health Inspection Service; July 2000.
Scrapie. Fact sheet. Washington, DC: US Department of Agriculture, Veterinary Services, Animal and Plant Health Inspection Service; September 1999.
Implementing the Amendment to the Annex of Council Directive 75/318/EEC: Demonstration of Compliance with the CPMP-TSE guideline. Briefing document. Doc. Ref: EMEA/CPMP/BSP/2962/99. London, England: European Agency for the Evaluation of Medicinal Products; November 15, 1999.
New Requirements for Medicinal Products Relating to Transmissible Spongiform Encephalopathies (TSEs). Letter to all Licence Holders. United Kingdom: Medicines Control Agency; July 7, 2000.
Certification of Suitability to the Monographs of the European Pharmacopoeia (revised version). Resolution AP-CSP (99) 4. Strasbourg, France: Council of Europe Public Health Committee (Partial Agreement), European Directorate for the Quality of Medicines. http://www.pheur.org.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rowland, S.S. Transmissible Spongiform Encephalopathy and Medicinal Products in the United States and Europe. Ther Innov Regul Sci 35, 993–1001 (2001). https://doi.org/10.1177/009286150103500337
Published:
Issue Date:
DOI: https://doi.org/10.1177/009286150103500337